MEMehtap Ertekin

Mehtap Ertekin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mehtap Ertekin has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Long-term outcomes of pediatric medulloblastoma before routine molecular classification: a 20-year single-center cohort study

    by Mehtap Ertekin, Aytul Temuroglu, Gokalp Rustem Aksoy, Mevlut Ozgur Taskapilioglu, Betul Sevinir

    Purpose Medulloblastoma is the most common malignant brain tumor of childhood. Although molecular classification has refined prognostication, long-term real-world outcomes from periods or settings without routine molecular subtyping remain clinically relevant. We report a 20-year single-center experience from a tertiary pediatric oncology center in Turkey. Methods We retrospectively analyzed 97 children diagnosed with Medulloblastoma at Uludag University between 2000 and 2020. Survival status was updated through 2025. Overall survival (OS) and event-free survival (EFS) were estimated using Kaplan–Meier analysis. Prognostic factors were assessed using log-rank tests and multivariate Cox regression for OS and EFS. Late effects among survivors were recorded. Results The cohort included 56 males and 41 females, with a median age of 7.0 years. Five-year OS and EFS were 73.9% and 69.9%, respectively, with a median follow-up of 70.2 months. Five-year OS improved from 57.1% in 2000–2010 to 83.6% in 2011–2020. Later treatment era independently predicted improved OS (HR, 0.30; 95% CI, 0.14–0.65; p = 0.002) and EFS (HR, 0.38; 95% CI, 0.20–0.75; p = 0.005). Anaplastic/large-cell histology independently predicted poorer OS and EFS. Baseline characteristics were largely similar between eras, although median age differed. Late effects were documented in 56 of 68 survivors (82%), most commonly motor or cerebellar dysfunction, growth failure, neurocognitive impairment, and hypothyroidism. Conclusion Survival improved across treatment eras and was not readily explained by a more favorable measured case mix. These findings provide pre-molecular era real-world benchmarks and highlight the importance of treatment standardization and structured survivorship care.

  • Open Access

    Laboratory-reassuring profiles in pediatric leukemia and lymphoma: a single-center cohort study

    by Mehtap Ertekin, Zühal Önder Siviş, Burcak Tatlı Güneş, Esin Özcan, Salih Gözmen

    Aims: Childhood leukemia and lymphoma may present with overlapping nonspecific symptoms, yet their initial laboratory profiles can differ substantially. Pediatric lymphoma, in particular, may present without cytopenia and with normal lactate dehydrogenase (LDH), potentially creating false reassurance.Methods: We conducted a retrospective single-center cohort study of 81 patients diagnosed with leukemia (n=49; B-ALL 28, T-ALL 7, AML 14) or lymphoma (n=32; NHL 17, Hodgkin lymphoma 15) between January 2024 and January 2026 at a tertiary pediatric hematology–oncology center. Clinical and laboratory findings were compared using Fisher’s exact and Mann–Whitney U tests. The primary analysis compared the prevalence of a laboratory-reassuring profile, defined as simultaneous absence of cytopenia and LDH ≤300 U/L. Results: The laboratory-reassuring profile was present in 16 of 32 lymphoma patients (50%) and in none of the 49 leukemia patients (0%; p

  • Long-term Survival and Relapse Patterns in Pediatric Hepatoblastoma: A 20-year Single-center Experience

    by Mehtap Ertekin, Aytul Temuroglu, Fatih Celik, Metin Demirkaya, Betul Sevinir

    Background: Despite advancements, managing high-risk and metastatic hepatoblastoma remains challenging. This study evaluates 2 decades of clinical experience to identify long-term prognostic drivers and the evolving role of event-free survival (EFS). Methods: This cohort consisted of 39 children with hepatoblastoma from 2004 to 2024. The clinical characteristics, PRETEXT, risk group, alpha-fetoprotein level, pulmonary metastasis, and treatment modalities were reviewed. The overall and event-free survival were estimated using the Kaplan-Meier method and log-rank tests. Univariable Cox regression was performed to evaluate the impact of pulmonary metastasis on EFS. Results: The mean age at diagnosis was 3.6±4.3 years. The 5-year OS and EFS rates were 81.2% and 75.0%, respectively. Six deaths and 9 events were recorded. OS was not significantly influenced by risk group ( P =0.093), PRETEXT stage ( P =0.177), and AFP ( P =0.214). Pulmonary metastasis at diagnosis was associated with poor EFS (log-rank P =0.048). In the univariable Cox model for EFS, pulmonary metastasis was associated with a higher risk for events (HR 3.83, 95% CI 0.91-16.10, P =0.067). Conclusions: Long-term overall survival was favorable in this cohort. Pulmonary metastasis emerged as the variable most closely linked to inferior event-free survival, whereas traditional clinical and staging variables were not significantly associated with overall survival.

  • Open Access

    Sleep Disturbance Patterns in Children with Leukemia and Lymphoma: Domain-Specific Associations with Hospitalization and Treatment Context

    by Mehtap Ertekin, Salih Gozmen

    Objectives: The importance of sleep disturbance as a component of supportive care in pediatric oncology has recently been recognized, but the characteristics of sleep for this particular disease category have yet to be elucidated. Methods: This cross-sectional study included 54 pediatric patients diagnosed with leukemia or lymphoma and 56 age- and sex-matched clinically stable children attending routine pediatric hematology outpatient follow-up for benign hematological conditions. Sleep was assessed using the Children’s Sleep Habits Questionnaire (CSHQ). Global and domain-specific sleep scores were compared. Multivariable linear regression was used to identify correlates of global sleep disturbance, including parental educational attainment. Within the patient group, recent hospitalization and corticosteroid exposure were modeled separately because of strong collinearity. Results: Patients had higher global CSHQ scores than the comparison group (53.56 ± 8.28 vs. 49.07 ± 8.09, p = 0.005; Cohen’s d = 0.55). Differences were most evident in sleep anxiety and parasomnias (exploratory subscale findings), whereas sleep duration did not differ significantly. In the whole-sample model, patient status (B = 4.16, p = 0.006) and higher parental educational attainment (B = −2.13, p < 0.001) were independently associated with global sleep disturbance. Within the patient group, recent hospitalization was the strongest clinical correlate of sleep burden (B = 11.18, p < 0.001; R2 = 0.433). Corticosteroid exposure was associated with higher sleep disturbance only in models excluding hospitalization. Conclusions: Children with leukemia and lymphoma showed a selective parent-reported sleep disturbance pattern characterized mainly by sleep anxiety and parasomnias rather than reduced sleep duration. Recent hospitalization and parental educational attainment appear to be important correlates of sleep burden in pediatric hematology-oncology care.

  • Open Access

    Clinical characteristics, risk factors, and short-term outcomes of pediatric thrombosis in hospitalized non-malignant patients: a single-center study

    by Mehtap Ertekin, Neryal Tahta, Zühal Önder Siviş, Burçak Tatlı Güneş, Esin Özcan, Salih Gözmen

    Aims: Thrombosis in pediatrics differs from that in adults and is mainly provoked. The main triggers include central venous catheterization, critical illness, infection, and immobilization. The factors associated with illness severity and short-term outcome in hospitalized children without cancer remain poorly defined. The aim of this study was to identify such factors and to describe short-term radiological outcomes.Methods: In this retrospective study, hospitalized non-cancer children (≤18 years old) with thrombosis were studied from October 2024 to July 2025. Data on demographics, risk factors, D-dimer levels, thrombophilia testing, treatment modalities, and radiographic responses at 1 and 3 months after diagnosis were collected.Results: Eighty-eight children (median age 2.0 years, IQR 0.0-11.2 years); 58.0% males. All thrombosis episodes occurred in the venous system, and 62.5% were related to the use of catheters. Immobility (48.9%) and sepsis (40.9%) emerged as the predominant risk factors. D-dimer median was 520 ng/ml (IQR 200-1136), with significantly higher levels observed among ICU/palliative care units than in other wards (p

  • Open Access

    Pediatric Nasopharyngeal Carcinoma: Survival Outcomes and Late Toxicity Burden from a 20-Year Single-Center Experience

    by Mehtap Ertekin, Aytul Temuroglu, Candan Demiroz Abakay, Betul Sevinir

    Objectives: Pediatric nasopharyngeal carcinoma (NPC) is rare and often presents at an advanced stage. Although multimodal treatment can achieve favorable survival, long-term survivors may experience substantial treatment-related morbidity. We aimed to evaluate survival outcomes according to stage and metastatic status and to characterize late toxicity in a 20-year single-center pediatric NPC series. Methods. We retrospectively reviewed 24 pediatric patients diagnosed with NPC between 2003 and 2023. Histology was classified according to WHO criteria, and tumors were staged using the AJCC TNM system. Overall survival (OS) and event-free survival (EFS) were estimated using the Kaplan–Meier method. Survival distributions were compared using the log-rank test. Late treatment-related toxicities documented during follow-up were recorded descriptively. Results: Twenty-four patients with WHO type III NPC were included. Fourteen patients had stage III disease and 10 had stage IV disease; three had distant metastasis at diagnosis. The median follow-up duration was 50.5 months. At last follow-up, 19 patients were alive and five had died. The estimated 5- and 10-year OS rates were both 72.7%, and the corresponding EFS rates were both 63.7%. Stage IV disease and metastatic presentation were associated with inferior OS. Dysphagia, malnutrition, xerostomia, fibrosis, hypothyroidism, and deafness were the most frequently recorded adverse health effects. Conclusions: This 20-year single-center experience shows that AJCC stage and metastatic status remain key determinants of survival in pediatric NPC. The high burden of late treatment-related complications highlights the importance of integrating long-term multidisciplinary survivorship surveillance into the care of pediatric NPC survivors.

  • Open Access

    Clinical Phenotypes and Glycopeptide Escalation Patterns in Pediatric Febrile Neutro-penia: Associations With Short-Term Outcomes and Acute Kidney Injury Risk

    by Neryal Tahta, Zuhal Onder Sivis, Mehtap Ertekin, Burcak Tatli Gunes, Silem Ozdem Alatas, Esin Ozcan, Salih Gözmen

    Febrile neutropenia (FN) in pediatric oncology is a clinically heterogeneous syndrome in which early antibiotic escalation decisions are frequently driven by nonspecific severity cues. We aimed to identify baseline clinical phenotypes of pediatric FN, to describe early glycopeptide escalation patterns across these phenotypes, and to examine their associations with short-term outcomes and acute kidney injury (AKI). We conducted a retrospective cohort study including 106 FN episodes in 82 pediatric oncology patients initially treated with piperacillin-tazobactam monotherapy. Baseline clinical and laboratory variables available within the first 6 hours of FN onset were used for unsupervised k-means clustering to derive latent clinical phenotypes. Early glycopeptide escalation was defined as initiation of vancomycin or teicoplanin within 48 hours. Associations with day-7 clinical outcomes and AKI were evaluated using cluster-robust multivariable regression and inverse probability of treatment weighting. Three distinct FN phenotypes were identified: a high-inflammatory/mucositis-dominant phenotype (39.6%), a hemodynamically severe phenotype (22.6%), and a lower-severity phenotype (37.7%). Early glycopeptide escalation occurred in 26.4% of episodes and was disproportionately concentrated in the high-inflammatory and hemodynamically severe phenotypes. AKI developed in 10.4% of FN episodes and clustered predominantly within escalation-prone phenotypes. After adjustment, early escalation was not associated with improved day-7 clinical success but was associated with a higher observed risk of AKI. Pediatric FN comprises distinct clinical phenotypes that differentially drive antibiotic escalation behavior and renal injury risk. A phenotype-informed approach may help optimize escalation decisions and potentially reduce preventable toxicity. However, given the observational design, these associations should be interpreted with caution.

  • Open Access

    Pediatric orbital masses from a tertiary pediatric oncology referral center: clinical characteristics and survival outcomes from a 20-year single-center experience

    by Mehtap Ertekin, Aytul Temuroglu, Gokalp Rustem Aksoy

    Pediatric orbital masses are uncommon and most reports originate from ophthalmology services, where benign lesions predominate; oncology-referral populations may differ and remain underreported. We reviewed children evaluated for proptosis and orbital mass at a tertiary pediatric oncology unit (2000–2020). Demographic features, diagnostic spectrum, tumor origin, age distribution, diagnostic approach, and survival outcomes were analyzed. Overall survival (OS) was estimated by Kaplan–Meier analysis and compared by log-rank testing. Prespecified exploratory comparisons included age (< 5 vs. ≥ 5 years), diagnostic approach, and metastatic neuroblastoma versus other malignant orbital tumors. A univariable Cox model explored the association between metastatic neuroblastoma and OS. Sixty patients were included (65% male), with median age of 4.74 years (IQR, 2.16–8.84 years). Malignant tumors comprised 88% (n = 53); benign lesions were 12% (n = 7) and mainly vascular. The most frequent diagnoses were metastatic neuroblastoma and optic pathway glioma (each 21.7%), followed by non-Hodgkin lymphoma and rhabdomyosarcoma (each 13.3%). Histopathology confirmed 85% (n = 51), whereas 15% (n = 9) were diagnosed radiologically, predominantly optic pathway gliomas. Diagnosis differed by age (< 5 vs. ≥ 5 years; p = 0.009), with metastatic neuroblastoma concentrated in children younger than 5 years (92.3%). Nine deaths occurred, all in malignant tumors. Metastatic neuroblastoma was associated with inferior overall survival and higher mortality risk than other orbital tumors. Pediatric orbital masses referred to oncology centers represent a high-risk population with a high malignancy rate. Rapidly progressive proptosis, particularly in children < 5 years, should prompt urgent evaluation for metastatic neuroblastoma.

  • Evaluation of clinical and radiological findings in children with juvenile idiopathic arthritis

    by Mehtap Ertekin, Müferet Ergüven

    Aim: Juvenile idiopathic arthritis (JIA) is the most prevalent chronic rheumatologic condition in children. Determining radiological progression in relation to clinical and laboratory parameters is crucial for initiating early intervention. This study aimed to investigate the association between diagnostic delay, human leukocyte antigen B27 (HLA-B27) positivity, and the development of late radiological changes in children with JIA.Methods: This retrospective single-center study included 96 patients diagnosed with JIA between January 2006 and April 2015. Demographic, clinical, laboratory, and radiological data were reviewed. Radiological changes emerging after one year of disease onset were defined as late radiological findings. Clinical features, laboratory markers, and treatment modalities were compared between patients with early and late radiological changes.Results: The mean age at diagnosis was 8.8 ± 4.0 years; 67.7% were female. Oligoarticular JIA was the most common subtype, occurring in 67 patients (69.8%), followed by systemic JIA in 20 patients (20.8%) and polyarticular JIA in 9 patients (9.4%). Late radiological changes were observed in 35 patients (36.5%). HLA-B27 positivity (20.0% vs. 6.6%, p=0.049), longer diagnostic delay (3.3 ± 2.0 vs 2.0 ± 1.8 years, p=0.002), higher joint involvement (5.6 ± 3.6 vs. 4.2 ± 2.7, p=0.033), and extra-articular findings (68.6% vs. 27.9%, p=0.001) were associated with late radiological changes. Antinuclear antibody (ANA) test positivity was inversely associated (40.0% vs. 62.3%, p=0.034). Conclusions: HLA-B27 positivity and diagnostic delay were associated with late radiological changes in children with JIA. Early diagnosis and close radiological monitoring may help prevent long-term joint damage.